Treat Theranos as a cautionary tale, not an investment opportunity: the proposed AI reboot is unproven, and no ticker or actionable trade was identified. The discussion offers no stock thesis or price target for CVS, WBA, or PFE; verify any health-tech partner’s claims independently rather than inferring a view on these companies’ shares.

Theranos (private company; no ticker)

• Holmes and Theranos reportedly raised about $500 million on claims that the Edison device could run many blood tests from a small sample. The podcast recounts that the device could not perform most of the tests as claimed and that some tests were run on conventional third-party equipment instead.
• Speakers cited evidence discussed in the episode—including doctored reports bearing Pfizer’s logo and demonstrations that allegedly misrepresented the technology—as reasons to view the case as fraud, not simply an ambitious startup that failed.
• The podcast says Holmes and her partner were again pitching investors and recruiting for a Theranos effort, this time involving AI, while Holmes was preparing to go to prison. This was described as an attempt to restart the business, not as a proven or successful venture.

Takeaways

• Treat the Theranos story as a warning about investing in high-stakes technology based on a compelling mission or founder pitch alone. Seek independent evidence that the product works as represented.
• For health-tech investments, verify test accuracy, real-world performance, customer use, revenue, and any claimed endorsements directly. Claims involving patient testing deserve particular scrutiny.
• The speakers’ discussion of a possible AI-enabled reboot does not establish that the technology or business is viable; it should not be taken as an investment recommendation.

CVS Health (CVS)

• CVS was mentioned as a potential retail partner for Theranos’s proposed blood-testing service. The service was presented as convenient and inexpensive, but the podcast says the underlying technology did not perform as broadly as represented.
• The discussion did not assess CVS’s financial exposure, current business prospects, or stock.

Takeaways

• The Theranos episode offers no direct view on CVS shares. Its relevant lesson is to distinguish a retailer’s involvement with a health-tech company from independent validation of that company’s product.

Walgreens Boots Alliance (WBA)

• Walgreens was described as a Theranos partner that was persuaded by documents and claims about the blood-testing technology. The podcast recounts testimony that reports bearing a Pfizer logo led Walgreens to believe Pfizer had authored them, though Pfizer had not.
• No financial impact on Walgreens or view on WBA shares was discussed.

Takeaways

• The episode does not provide a stock thesis for WBA. It does illustrate why investors should examine how a company vets partners and verifies consequential technical claims.

Pfizer (PFE)

• Pfizer was mentioned in connection with Theranos: the podcast says Holmes admitted adding pharmaceutical-company logos to reports, and Pfizer representatives testified they had not authored the reports.
• Pfizer was not discussed as an investment, and no view on PFE shares was offered.

Takeaways

• The mention is about alleged misuse of Pfizer’s name, not an assessment of Pfizer’s business or stock.

Early-stage health-tech and venture investing

• The podcast names Tim Draper as an early champion of Holmes and says he was among the investors who suffered financially. The speakers suggested that hearing his perspective would be interesting; they did not provide details of his losses.
• One speaker speculated that Andreessen Horowitz (a16z) might back Holmes in a future round after her release. This was speculation, not a report that a16z had committed to invest.

Takeaways

• The episode highlights the risks of backing early-stage health technology before core claims are independently verified. A founder’s reputation, a large market opportunity, or prominent investors are not substitutes for evidence that the product works.
• Neither Tim Draper’s involvement nor the hypothetical a16z comment amounts to a current investment recommendation or confirmed investment opportunity.